TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 2.4% – Should You Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s stock price traded down 2.4% during trading on Monday . The stock traded as low as $1.65 and last traded at $1.65. Approximately 20,405 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 85,972 shares. The stock had previously closed at $1.69.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

TransCode Therapeutics Trading Down 2.4%

The firm has a market capitalization of $27.93 million, a price-to-earnings ratio of -0.03 and a beta of 1.16. The company has a fifty day moving average price of $4.56 and a 200-day moving average price of $6.50.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings results on Friday, August 14th. The company reported ($7.17) EPS for the quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.